Individuals and families covered by HSA-qualified, high-deductible health plans could see significant reductions in their out-of-pocket expenditures over the next 14 months as generic versions of seven of the world's 20 best-selling drugs, including cholesterol fighter Lipitor and blood thinner Plavix, hit the market.
According to the London research firm EvaluatePharma Ltd, best selling drugs with about $255 billion in global annual sales will go off patent between now and 2016. Generic competition is expected to slash the cost to patients and companies that provide health benefits.
The lower cost prescription drugs could perhaps directly benefit most those who have HSA plans that require insureds to pay the full (usually discounted) cost of most prescription drugs until they have reached their plan's annual deductible limit.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
